CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Merck's[1][3] release, dated January 7, 2026, says it 'today announced the successful completion of the cash tender offer' for Cidara, with the tender expiring 11:59 p.m. ET on January 6.On 7 January 2026 Merck announced the completion of its cash tender offer for Cidara Therapeutics at US$221.50 per share, gaining CD388, a long-acting antiviral for preventing influenza.
1.00